JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB269618

Human GPD2 knockout A-431 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

GPD2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9; X = 32 bp deletion, 31 bp deletion, 4 bp deletion; Frameshift: 100%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Next Generation Sequencing - Human GPD2 knockout A-431 cell line (AB269618)
  • NGS

Supplier Data

Next Generation Sequencing - Human GPD2 knockout A-431 cell line (AB269618)

Knockout achieved by CRISPR/Cas9; X = 32 bp deletion, 31 bp deletion, 4 bp deletion; Frameshift : 100%

Key facts

Cell type

A-431

Species or organism

Human

Tissue

Skin

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Mutation description

Knockout achieved by CRISPR/Cas9; X = 32 bp deletion, 31 bp deletion, 4 bp deletion; Frameshift: 100%

Disease

Epidermoid Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab269618-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human GPD2 knockout A-431 cell line kit component", "number":"AB269618-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab269618-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"Human GPD2 knockout A-431 cell line kit component", "number":"AB269618-CMP01", "productcode":"" }, { "size":"1 x 1000000 Cells/vial", "name":"Human wild-type A-431 cell line kit component", "number":"AB269618-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
GPD2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
-196°C|-80°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glycerol-3-phosphate dehydrogenase 2 (GPD2) also known as GPDM-m and mGPDH is an enzyme that belongs to the glycerol-3-phosphate dehydrogenase family. GPD2 weighs approximately 74 kDa and is expressed in several tissues including the liver kidney and muscle. It primarily localizes in the mitochondrial inner membrane. Mechanically GPD2 catalyzes the oxidation of glycerol-3-phosphate to dihydroxyacetone phosphate playing an important role in energy metabolism by participating in the glycerol phosphate shuttle. This shuttle facilitates the transfer of reducing equivalents across the mitochondrial membrane.
Biological function summary

GPD2 plays a role in cellular energy production by linking lipid metabolism to carbohydrate metabolism. It forms part of a complex system supporting oxidative phosphorylation by transferring electrons to the mitochondrial electron transport chain. The activity of GPD2 helps sustain the NAD+/NADH balance which is essential for maintaining cellular redox states. Through its function GPD2 contributes to metabolic flexibility allowing cells to adapt to changes in fuel availability.

Pathways

GPD2 is involved in important energy production pathways such as the glycerol phosphate shuttle and the oxidative phosphorylation pathway. These pathways are important for efficient ATP production in eukaryotic cells. GPD2 interacts with other metabolic proteins like cytosolic glycerol-3-phosphate dehydrogenase (GPD1) which works in tandem to facilitate the shuttle of reducing equivalents between cytosol and mitochondria. Such processes ensure continuous energy supply necessary for cellular functions especially under conditions where carbohydrates and lipids serve interchangeably as energy sources.

GPD2 associates with conditions such as obesity and type 2 diabetes where energy metabolism is often disrupted. Altered GPD2 activity can lead to impaired mitochondrial function contributing to the pathogenesis of these metabolic disorders. Furthermore GPD2 links to proteins implicated in these diseases such as insulin receptor substrates and oxidative stress markers which further influence glucose and lipid homeostasis. Understanding GPD2's interaction with these elements helps in uncovering potential therapeutic targets for such diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com